In a setback, FDA orders Gilead to hit the brakes on their late-stage, $5B cancer play

Gilead’s $5 billion drug magrolimab has run into a serious setback. The FDA ordered Gilead to halt enrollment on their studies of the drug in combination with azacitidine after investigators reports revealed an “apparent imbalance” in the suspected unexpected serious adverse reactions between study arms. “While no clear trend in…

...

Click to view original post